DarioHealth (DRIO)
(Delayed Data from NSDQ)
$1.60 USD
+0.03 (1.91%)
Updated May 6, 2024 04:00 PM ET
After-Market: $1.61 +0.01 (0.63%) 6:22 PM ET
1-Strong Buy of 5 1
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DRIO 1.60 +0.03(1.91%)
Will DRIO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DRIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DRIO
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
DRIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for DRIO
Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes
DarioHealth files to sell 15.73M shares for holders
DarioHealth files to sell 15.73M shares of common stock for holders
Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution
DarioHealth's cardiometabolic suite selected by two employers